Daily outlook for January 14th: DAX firmer. Bayer and RWE in focus! – columns

In the stock markets, the majority of investors held back with larger commitments. The look at the corona infection numbers dampened the mood. Good production figures from industry in the euro zone only encouraged buyers selectively. The DAX® was largely below the 14,000 point mark today.

After the significant increase in yields in the past few days, the bonds turned into the consolidation course. For the most part, bond prices rose somewhat and yields fell somewhat accordingly. The yield on 10-year government bonds fell to minus 0.52 percent. In the case of precious metals, investors continued to be cautious. The price of gold stagnated at $ 1,860 per troy ounce and silver at $ 25.50. After a late rally last night, oil prices turned slightly south again today. The trend is still upwards.

Company in focus

Bayer has today for the media day “Transforming Healthcare. Transforming Bayer ”. In it, Pharma CEO Stefan Oelrich stated that Bayer has long been more than the blockbuster drugs Eylea and Xeralto, and that investors have underestimated this sector. The share rose sharply today. By March, Oelrich wants to present a plan of how Bayer wants to position itself in the pharmaceutical sector in the future. After the strong year 2020, the German postal service also optimistic for 2021. The share then rose to the area of ​​the record high. RWE benefited from positive analyst comments. Real estate stocks such as German living and Vonovia and hydrogen stocks – read on Global Hydrogen Index. KKR sells its stake in the media group ProSiebenSat.1. The share then fell over six percent.

Hella and Südzucker will present figures for the past fiscal quarter tomorrow. This week the highly regarded Consumer Electronics Show takes place.

Important appointments

  • China – foreign trade
  • USA – Initial Jobless Claims

Please note the important information and the disclaimer.

This information does not constitute investment advice, but advertising. The public offer is made exclusively on the basis of a securities prospectus approved by the Federal Financial Supervisory Authority (“BaFin”). Approval of the prospectus should not be understood as a recommendation to purchase these UniCredit Bank AG securities. Only the prospectus including any supplements is relevant and the Final Terms. It is recommended that you read these documents carefully before making any investment decision in order to fully understand the potential risks and rewards of investing. You are about to acquire a product that is not easy and can be difficult to understand.

How the HVB products work

Related Articles

Back to top button